Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365820 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
A Phase 2 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 670
- Enrollment target
NCT00365820 is a Phase 2 study that was terminated before completion, run by Novartis. The registered enrollment target is 670 participants.
The verdict
NCT00365820, a Phase 2 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 670 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365820
The ClinicalTrials.gov registry entry for NCT00365820 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00365820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365820 about?
NCT00365820 is a clinical study titled "Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain". This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.
What is the current status of trial NCT00365820?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 670 participants. The study started on 2006-07. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00365820?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00365820?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.